| 764508 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
795 APVO603: a dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTM technology designed to deliver a conditional T cell/NK response against solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.795 |
Nelson Michelle, Lucas Ashly, Gottschalk Rebecca, McMahan Catherine, Gross Jane, Ramos Hilario |
| 764507 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
793 Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platforms |
2021-11-01 |
10.1136/jitc-2021-sitc2021.793 |
Moniz Raymond, Vakkasoglu Ahmet, Merazga Zohra, Daigneault Tina, Quayle Steve, Girgis Natasha, Seidel Ronald, Ross John, Low Simon, Suri Anish |
| 764506 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
792 Creating an immune-favorable tumor microenvironment by a novel anti-CD39/TGFβ-Trap bispecific antibody |
2021-11-01 |
10.1136/jitc-2021-sitc2021.792 |
Lu Hongtao, Sun Dawei, Sun Jun, Geng Yanan, Zhang Jinhui, Gao Rui, Li Lei, Wu Zhihao, Tang Lily, Qiu Yangsheng |
| 764505 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
789 Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule to enhance targeted tumor cytotoxicity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.789 |
Dufort Fay, Leitheiser Christopher, Mudd Gemma, Kristensson Julia, Rezvaya Alexandra, Repash Elizabeth, Haines Eric, Gaynor Katie, Uhlenbroich Sandra, Urbonas Liudvikas, Allen Heather, Harrison Helen, Chen Liuhong, Brandish Philip, McDonnell Kevin, Keen Nicholas |
| 764504 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
788 A novel T- lymphocyte binding aptamer assembled into a bispecifc compound for the treatment of solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.788 |
Levy Irit Carmi, Lavi Erez, Hanin Neta Zilony, Pode Zohar, Mizrahi Karin, Farhi Ronit, Paz Anastasia, Reiss Neria, Shimoni Chen, Buravenkov Vitaliy, Levy-Efrati Liron, Haimovich Rotem, Glaich Ohad, Liron Itay, Zazrin Hadas Aharoni, Bachelet Ido, Berger Raanan, Neev Guy |
| 764503 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
787 Natural killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines |
2021-11-01 |
10.1136/jitc-2021-sitc2021.787 |
Bykova Katrina, Faber Matthew, Liu Ke, Siddiqi Noor, Bernett Matthew, Bonzon Christine, Diaz Juan, Nam Dong Hyun, Avery Kendra, Qi Jing, Rashid Rumana, Bahjat Rena, Desjarlais John |
| 764502 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
640 Stem-like CD4 T cells in cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.640 |
Cardenas Maria, Prokhnevska Nataliya, Jansen Caroline, Master Viraj, Kissick Haydn |
| 764501 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
639 PIK3IP1/TrIP immune regulation on CD8+ T cells restricts anti-tumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.639 |
Murter Benjamin, Banerjee Hridesh, Szymczak-Workman Andrea, Kane Lawrence |
| 764500 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
638 Hypoxia reprograms natural killer cells and impairs their therapeutic potential |
2021-11-01 |
10.1136/jitc-2021-sitc2021.638 |
Kennedy Philippa, Arvindam Upasana Sunil, Ettestad Brianna, Phung Shee Kwan, Kile Quinlan, Hinderlie Peter, Li Yunmin, Lim James, Miller Jeffrey, Felices Martin |
| 764499 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
637 Exploring the impact of immunotherapy on cancer patients' real world experience |
2021-11-01 |
10.1136/jitc-2021-sitc2021.637 |
Nichols Helen, Schwartz Cynthia, Wu Elise |
